OverviewChartNewsTraderScreen

UniCredit Knock-Out Argenx SE/  DE000HD9QYV0  /

Frankfurt Zert./HVB
2024-11-15  7:11:30 PM Chg.-2.350 Bid7:15:09 PM Ask7:15:09 PM Underlying Strike price Expiration date Option type
4.940EUR -32.24% 5.040
Bid Size: 1,000		 6.130
Ask Size: 1,000		 - 492.4298 EUR 2078-12-31 Call
GlobeNewswire 08-28 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 08-26 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 08-12 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 07-25 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire 07-18 argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...
GlobeNewswire 07-16 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...
GlobeNewswire 07-08 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
GlobeNewswire 06-25 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire 06-21 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire 06-17 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire 06-13 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire 06-04 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 05-09 argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 05-07 argenx announces results of Annual General Meeting of Shareholders
GlobeNewswire 05-07 argenx to Present at BofA Securities 2024 Health Care Conference
GlobeNewswire 05-02 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire 04-16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire 03-27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire 03-26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GlobeNewswire 03-26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire 03-07 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire 02-29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire 02-26 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 02-22 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...
GlobeNewswire 02-20 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...